CGRPtargeted
CGRPtargeted is a biopharmaceutical company focused on developing and commercializing therapeutics targeting calcitonin gene-related peptide (CGRP), a neuropeptide involved in various physiological processes, including pain modulation, inflammation, and vasodilation. The company's primary goal is to create innovative treatments for conditions characterized by excessive CGRP activity, such as migraine, cluster headache, and certain types of pain.
The company's lead product, erenumab, is a fully human, monoclonal antibody designed to selectively neutralize CGRP.
CGRPtargeted's approach involves a combination of in-house research and development, as well as strategic partnerships with
In addition to erenumab, CGRPtargeted is exploring other potential CGRP-targeting therapies, including small molecule inhibitors and
CGRPtargeted is headquartered in Cambridge, Massachusetts, and operates as a private company. The company was founded